FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity-Reference-Cited by-同舟云学术

FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity

Published:2018-04-03 Issue:4 Volume:22 Page:353-363
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Whiteside Theresa L.¹

Affiliation:

1. Departments of Pathology, Immunology and Otolaryngology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Funder

National Institutes of Health

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2018.1451514

Reference113 articles.

1. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

2. The role of regulatory T cells in cancer immunology

3. Definition of two pathways for generation of suppressor T-cell activity.

4. Roles of regulatory T cells in cancer immunity

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy;Frontiers in Immunology;2024-09-09

2. Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications;Frontiers in Immunology;2024-09-03

3. Updates on the role of leukocyte cell-derived chemotaxin-2 in inflammation regulation and immunomodulation;Cytokine;2024-09

4. lncRNA signature mediates mitochondrial permeability transition-driven necrosis in regulating the tumor immune microenvironment of cervical cancer;Scientific Reports;2024-07-29

5. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors;Seminars in Immunopathology;2024-07-25